MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bbrep.2026.102713

Медицинская библиотека · Biochemistry and biophysics reports · 2026

Evaluation of oxidative stress and coagulation factors in MS patients throughout both relapse and remission stages.

Naseri Nima, Harirchian Mohammad Hossein, Khodadadi Iraj, Ghiasian Masoud, Askari Hossein, Abbasi Ebrahim

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Relapsing-remitting Multiple Sclerosis (RRMS) is characterized by inflammatory attacks on myelin. Previous studies have shown the vital role of coagulation factors, inflammation, and oxidative stress in multiple sclerosis (MS). Hence, changes in these factors in relapse occurrence could propose novel therapeutic and diagnostic targets.The blood samples were collected during relapse status. Then, patients were followed up for three months with no difference in disease modifying treatments (DMTs)-naive status, and the second blood samples were collected in the remission phase.

METHODS

The coagulation factors were measured in 24 RRMS (13F/11M) patients and 24 healthy controls (12F/12 M). Oxidative stress markers such as total oxidant status (TOS), malondialdehyde (MDA), total antioxidant capacity (TAC) and inflammatory biomarkers such as IL-6, ferritin, C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR) were measured in both relapse and remission phases.

RESULTS

The expanded disability status scale (EDSS) was considerably higher in relapse versus remission status (p = 0.001). The results indicate that d-dimer, as a coagulation marker, ferritin, CRP, ESR, MDA, and TOS are higher in relapse vs remission (p < 0.05). Besides, further analysis showed that fibrinogen, ferritin, IL-6, and TOS were significantly different in RRMS vs the control (p < 0.05). These parameters showed no significant correlation between EDSS with coagulation, inflammatory, and oxidative markers (p > 0.05).

CONCLUSION

Our results showed that the levels of fibrinogen, TOS, ferritin, and IL-6 may have diagnostic efficacy in MS vs control. This study has some limitations. The first was the follow-up of RRMS candidates in relapse and remission. The second is that we did not measure the coagulation, inflammatory, and oxidative markers in the CSF sample.

Для цитирования: Naseri Nima, Harirchian Mohammad Hossein, Khodadadi Iraj, Ghiasian Masoud, Askari Hossein, Abbasi Ebrahim. Evaluation of oxidative stress and coagulation factors in MS patients throughout both relapse and remission stages.. Biochemistry and biophysics reports. 2026. DOI: 10.1016/j.bbrep.2026.102713.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.